Clearmind Medicine (CMND) announced the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders. The patent application covers the use of 3-Methylmethcathinone in combination with Palmitoylethanolamide. This combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Clearmind completes clinical site initiations for AUD trial
- Clearmind Medicine completes initiation of AUD Phase I/IIa trial
- Psychedelic: MindMed announces dosing in Phase 3 Emerge study
- Clearmind Medicine receives notice of allowance for U.S. patent
- Clearmind Medicine launches first U.S. clinical site for AUD trial